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Remifentanil post-conditioning attenuates cardiac
ischemia–reperfusion injury via j or d opioid
receptor activation
G. T. C. WONG, R. LI, L. L. JIANG and M. G. IRWIN
Department of Anaesthesiology, University of Hong Kong, Hong Kong
Background: Ischemic pre- or post-conditioning of the heart
has been shown to involve opioid receptors. Remifentanil, an
ultra-short-acting selective m opioid receptor agonist in clinical
use, pre-conditions the rat heart against ischemia–reperfusion
injury. This study investigates whether remifentanil post-con-
ditioning is also cardioprotective.
Methods: Remifentanil post-conditioning (5-min infusion
at 1.5, 10–20 mg/kg/min) or ischemic post-conditioning
(three cycles of a 10 s reperfusion interspersed with a 10 s
ischemia) was induced in an open-chest rat heart model of
ischemia and reperfusion injury, in the presence or absence
of nor-binaltorphimine, naltrindole or CTOP, specific k, d
and m opioid receptor antagonists, respectively. The same
sequence of experiments was repeated in the isolated heart
model using the maximal protective dose of remifentanil
from the dose–response studies.
Results: Both ischemic and remifentanil post-conditioning
reduced the myocardial infarct size relative to the control
group in both models. This cardioprotective effect for both
post-conditioning regimes was prevented by the prior
administration of nor-binaltorphimine and naltrindole
but not CTOP. The sole administration of the antagonists
had no effect on the size of myocardial infarction.
Conclusions: These results indicate that remifentanil
post-conditioning protects the heart from ischemia–reper-
fusion injury to a similar extent as of ischemic post-
conditioning. This protection involves k and d but not m
opioid receptor activation. This drug has great potential as
a clinical post-conditioning modality as it can be given
in large doses without prolonged opioid-related side
effects.
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CARDIAC post-conditioning refers to therapeuticmaneuvers administered just before final re-
perfusion that attenuate ischemia–reperfusion in-
jury. Ischemic post-conditioning involving staccato
reperfusion reduces infarct size (IS) to an extent
comparable to that achieved by pre-conditioning,1
and molecular studies have implicated several
common components and pathways.2 Opioid re-
ceptors are involved in ischemic post-conditioning,
as the latter can be blocked by the peripherally
restricted opioid antagonist naloxone methiodide3
and the d-specific antagonist naltrindole (NTD).4
Not until recently has the role of m receptors in
post-conditioning been specifically addressed5 as it
has traditionally been thought to be absent from
the heart,6 although more recent binding studies
have challenged this.7
Remifentanil, a selective m agonist, pre-condi-
tions the heart in the intact rat in part via m receptor
activation, possibly in a location outside the heart.8,9
As common reperfusion injury salvage pathways
may be triggered by pre- and post-conditioning,10
remifentanil could potentially post-condition the
myocardium. This study, evaluates whether remi-
fentanil is cardioprotective when administered in a
post-conditioning fashion and compares its effect
with that of ischemic post-conditioning. The relative
role of opioid receptor subtypes in both regimes was
also investigated by the use of subtype-specific
opioid receptor antagonists.
Material and methods
All procedures were approved by the local Com-
mittee for the use of live animals in teaching
and research. Experiments were conducted using
8-week-old male Sprague–Dawley rats weighing
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300 25 g, which were housed in separate cages,
given free access to food and water, except before
the study, and were exposed to alternate 12-h light
and dark cycles. A total of 114 animals were used for
in the vivo and 74 for the isolated heart experiments.
In vivo induction of ischemia–reperfusion injury
An anesthetized open-chest model of ischemia and
reperfusion injury was used. The anesthetic and
surgical preparation to the point of post-condition-
ing and the IS determination have been described in
detail previously.11 In short, anesthesia was induced
using pentobarbitone (50 mg/kg) and maintained
with boluses of 25 mg/kg 90 min after induction.
The heart was exposed via left thoracotomy at the
fifth intercostal space. Repeated cycles of regional
ischemia and reperfusion were made by tightening
or releasing the snare placed at the origin of the left
coronary artery. More prolonged ischemia involved
securing the sutures with a mosquito hemostat.
Ischemia was confirmed by cardiac cyanosis, a
substantial decrease in the mean arterial pressure
and electrocardiographic changes.
Isolated rat heart preparation
After the removal from the anesthetized rat, the
heart was immediately perfused by the Langen-
dorff method, and subsequently converted to the
working heart model (preload 15 cmH2O, afterload
80 cmH2O). Modified Krebs–Henseleit bicarbonate
buffer was used as the perfusion buffer (K–H
buffer, mM: NaCl 118, KCl 4.7, CaCl2 2.0, MgSO4
1.2, KH2PO4 1.2, EDTA 0.5, NaHCO3 25, glucose 11,
pH 7.4, 37 1C, 95% O215% CO2 gas mixture).
Electrocardiograms and indices of left ventricular
performance pressure [left ventricular developed
pressure (LVDP), left ventricular end diastolic
pressure (LVEDP), positive and negative maximum
left ventricular pressure derivative (1dP/dt and
dP/dt)] were measured using a Power-Lab mon-
itoring system with a Mikro-Tip Pressure Catheter
(AD Instruments, Colorado Springs, CO). After an
initial stabilization period of 15 min, ligation of the
left coronary artery was performed using a 6-0
prolene loop, along with a snare occluder, to mimic
a regional ischemia condition for 30 min, followed
by 120 min of reperfusion.
Myocardial IS determination
After the 120 min of reperfusion, the hearts from
the in vivo were excised and transferred to a
Langendorff apparatus. Each heart was immedi-
ately perfused with normal saline for 1 min at a
pressure of 100 cmH2O to remove residual blood.
The left coronary artery was re-occluded and 0.25%
Evans blue dye was injected to stain the normally
perfused region of the heart. Evans blue negative
area represented the area at risk (AAR) from
occlusion of the left coronary artery. The hearts
were then frozen, cut into 2 mm slices, incubated at
37 1C for 20 min in 1% 2, 3, 5-triphenyltetrazolium
(Sigma Chemical Company, St Louis, MO) in phos-
phate buffer at pH 7.4 and then immersed in 10%
formalin for 20 min to enhance the contrast of the
stain. The areas of infarct (triphenyltetrazolium
negative) and the risk zone for each slice were
traced and digitized using a computerized-plani-
metry technique (SigmaScan 4.0, Systat Software
Inc., Richmond, CA). The volumes of the left
ventricles, IS and AAR were calculated by multi-
plying area with slice thickness and summing the
product. The IS was expressed as a percentage of
the AAR (IS/AAR), and this ratio was used to
compare the differences between the groups.
Treatment protocols (Fig. 1)
Intact animal studies. All animals were subjected to
30 min of ischemia, followed by 120 min of reperfu-
sion. Rats were omitted from further data analysis
if severe hypotension (arterial mean blood pressure
o30 mmHg) or intractable ventricular fibrillation
occurred. At 5 min before the onset of reperfusion,
the animals were allocated to different treatments
according to a predetermined randomized se-
quence. All the drugs used were dissolved in
normal saline for administration.
Dose–response studies. For a negative control group,
normal saline was infused for a period of 5 min
beginning just before reperfusion. Remifentanil
post-conditioning was evaluated using a 5-min
infusion of the drug at 1, 5, 10 or 20mg/kg/min
of body weight (GlaxoSmithKline Limited, Hong
Kong, Hong Kong). In order to achieve near-
steady-state levels at reperfusion, the infusion
was commenced 5 min before the release of the
snare occluder. For a positive control, ischemic
post-conditioning was used and comprised of three
cycles of 10 s of reperfusion and 10 s of ischemia
before the final reperfusion.
This regime was chosen based on previous
studies in a rat model that was shown to be
effective.12,13 The remifentanil dose at which max-
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imal protection occurred was selected for the
antagonists and isolated heart studies.
Antagonist studies. Each of the antagonists was
given 15 min before reperfusion to evaluate any
intrinsic effects they may have had on myocardial
IS. These compounds were NTD, a d opioid
receptor selective antagonist,14 D-Phe–Cys–Tyr-D-
Trp–Orn–Thr–Pen–Thr–NH2 (CTOP), a m opioid
receptor selective antagonist,15 and nor-binaltor-
phimine (nor-BNI), a k opioid receptor selective
antagonist16 (Sigma Chemical Company). These
selective opioid receptor antagonists were dis-
solved in normal saline and administered as a
bolus at the following doses: NTD (5 mg/kg); nor
BNI (5 mg/kg) and CTOP (1 mg/kg). Both ischemic
post-conditioning and remifentanil post-condition-
ing (20mg/kg/min) were then performed in the
presence of individual antagonists administered
15 min before reperfusion.
Isolated heart studies. The same sequences of experi-
ments were performed in the isolated heart sub-
jected to simulated ischemia and reperfusion. Only
the dose of remifentanil that produced the maximal
reduction of IS in the intact animal was used in the
isolated heart study. Although it is unlikely that
remifentanil will reach the ischemic myocardium,
it was introduced 5 min before reperfusion to
mimic the in vivo preparation and continued for
5 min after the release of the snare occlude.
Statistical analysis
The primary outcome is myocardial IS, expressed
as percentage of the area at risk (IS/AAR). Previous
data from our laboratory using this model of
cardiac ischemia–reperfusion injury indicated the
expected IS/AAR of the control group to be be-
tween 50% and 60% and the expected magnitude of
IS/AAR reduction to be 40–50%. Therefore, at least
five animals per group are required to yield a
power of 80% and a P-value of 0.05. All data are
expressed as mean  SD, and were obtained from
six to seven separate animals per group. Statistical
significance was determined by one-way analysis
of variance (ANOVA), with application of Bonfer-
roni correction if significant F ratios were obtained.
Hemodynamic data were analyzed using one-way
ANOVA for between-group comparisons and re-
peated measure ANOVA for comparisons between
time points (SPSS version 16.0 for windows).
Results
A total of 114 animals completed the in vivo
experiments. Nineteen rats were excluded from
further analysis as they developed refractory hy-
potension (n5 4) and ventricular fibrillation
(n5 15) during the induction of regional ischemia.
They have yet received any experimental drugs. A
total of 74 rats were used for the isolated heart
preparations.
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(mins)
0 15025 30 3515
CON Ischemia Reperfusion
Ipoc ReperfusionIschemia
Repoc Ischemia Reperfusion
NTD
norBNI
CTOP
Antagonist
Control
Ischemia Reperfusion
Ipoc + NTD
Antagonist +
Ipoc
Ischemia Reperfusion
Repoc + NTD
Repoc + norBNI
Repoc + CTOP
Antagonist
+Repoc
Ischemia Reperfusion
Normal Saline
Infusion (5 min)
Ischemia
Postconditioning
Remifentanil
Infusion (5 min)
Antagonist
Administration
Ipoc + CTOP
Ipoc + norBNI
Fig. 1. Study design for in vivo and
isolated heart preparation experiments.
Ischemia–reperfusion injury was induced
by 30min of left coronary artery ligation,
followed by 120min of reperfusion. CON,
control; Ipoc, ischemic post-conditioning
(three cycles of 10 s of ischemia alternat-
ing with 10 s of reperfusion); Repoc,
remifentanil post-conditioning (1, 5, 10
or 20mg/kg/min); NTD, naltrindole; nor
BNI, nor-binaltorphimine and CTOP,
D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-
Thr-NH2.
Remifentanil post-conditioning
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In vivo hemodynamic data
The hemodynamic data for the dose–response
studies are presented in Table 1, and those for the
antagonist experiments are presented in Table 2.
Hemodynamic values including heart rate (HR),
mean arterial blood pressure (MAP) and rate–
pressure product (RPP) did not differ between
groups (P40.05) at baseline at the end of the
ischemic or reperfusion periods for both series of
experiments. For the dose–response experiments,
remifentanil post-conditioning reduced the HR and
RPP, except for the 10mg/kg dose. Both the 5 and
the 20mg/kg/min dose reduced the MAP. In the
antagonist experiments, the HR and RPP in all the
groups were also significantly lower during post-
conditioning compared with the control group,
with the MAP reduced only in the remifentanil-
containing groups.
In vivo IS comparisons
The AAR ranged from 0.36 0.02 to 0.44 0.03 cm3
and there were no significant differences between
the treatment groups. The IS/AAR was reduced by
remifentanil post-conditioning at doses of 10mg/
kg/min (40  4%) and 20mg/kg/min (39  6%), as
well as ischemic post-conditioning (40  6%) when
compared with the control group (55  7%)
(Po0.05) (Fig. 2). Although there was a reduction
in IS/AAR using 5mg/kg/min (45.  6%), it did
not reach statistical significance when compared
with the control (P5 0.07). However, there was no
difference in the infarct-sparing effect between the
two modes of post-conditioning (P5 1.0). The ad-
dition of NTD or nor-BNI before both ischemic and
remifentanil pre-conditioning prevented their pro-
tective effects. However, CTOP had no significant
effect on either post-conditioning regime. The sole
administration of individual opioid receptor an-
tagonists did not change the IS compared with the
control (Fig. 3).
Hemodynamic indices in the isolated heart
The HR and indices of left ventricular performance
are presented in Table 3. There were no differences
between groups at baseline, during ischemia, at 60
and 120 min after reperfusion for all indices. There
were also no differences between groups for the
positive and negative dp/dt values for all time
points. Remifentanil post-conditioning reduced
the LVDP, LVEDP and HR at 10 min after reperfu-
sion. Repoc1nor-BNI reduced LVDP and HR at
10 min after reperfusion, whereas Repoc1NTD and
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Table 1
Hemodynamic data of the dose response studies.
n Baseline Ischemia Post-conditioning Reperfusion
MAP (mmHg)
CON 6 99  11 96  10 93  10 77  16*
IPOC 6 107  9 102  11 81  3* 90  10*
Repoc 1 6 121  21 80  16* 71  20* 93  15
Repoc 5 6 107  12 77  8* 63  18* ,w 83  18
Repoc 10 6 122  24 93  19* 73  22* 102  19
Repoc 20 7 103  5 97  11 65  8* ,w 88  11
HR (per minute)
CON 6 423  24 406  12 413  18 368  21*
IPOC 6 423  21 416  19 373  14* 390  14*
Repoc 1 6 378  46 377  44 323  40w 341  39
Repoc 5 6 392  34 396  25 353  50w 325  23
Repoc 10 6 380  48 382  57 370  31 366  52
Repoc 20 7 417  21 408  16 345  14* ,w 385  19
RPP (mmHg/min/1000)
CON 6 42  4 39  4 38  4 28  6*
IPOC 6 45  4 43  3 30  2* 34  4*
Repoc 1 6 45  9 30  6* 23  8* ,w 32  7*
Repoc 5 6 42  4 31  5* 23  9* ,w 27  7*
Repoc 10 6 46  9 36  10* 27  10* 38  11
Repoc 20 7 42  4 39  5* 22  4* ,w 34  5*
Data were collected at the end of the respective periods and are presented as mean  SD; data are compared against baseline value
within-group using a repeated measure analysis of variance (ANOVA) and between groups are made using one-way ANOVA, with the
Bonferroni correction applied for multiple comparisons if significant F ratios were obtained.
*Po0.05 vs. baseline (within-group comparison).
wPo0.05 vs. control (between-group comparison).
MAP, mean arterial pressure; HR, heart rate; RPP, rate pressure product; CON, control group; Repoc, remifentanil post-conditioning.
G. T. C. Wong et al.
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Repoc1CTOP also reduced LVDP at the same time
point.
Isolated heart IS comparisons
The AAR ranged from 0.38  0.07 to
0.55  0.06 cm3. The IS/AAR for both ischemic
post-conditioning (44  5%) and remifentanil
post-conditioning (42  4%) were significantly
smaller relative to the control group (59.0  3%)
(Po0.01). However, there was no difference in the
infarct-sparing effect between the two modes of
post-conditioning (P5 0.38). Similar to the in vivo
data, the addition of NTD or nor-BNI before both
ischemic and remifentanil pre-conditioning pre-
vented their protective effects. The addition of
CTOP also had no significant effect on either
post-conditioning regime. The sole administration
of individual opioid receptor antagonists did not
change the IS compared with the control (Fig. 4).
Discussion
The results of this study have demonstrated that
the application of an exogenous opioid in the form
of remifentanil after the start of the ischemic event
diminishes cardiac ischemia–reperfusion injury to
an extent similar to that from ischemic post-con-
ditioning, using both the intact rat and the isolated
heart perfusion model. There is an indication that
the degree of protection is related to the dose
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Table 2
Hemodynamic data antagonist in vivo experiments.
n Baseline End of ischemia
period
End of post-conditioning
period
End of reperfusion
period
MAP (mmHg)
CON 6 99  11 96  10 93  10 77  16*
NTD 6 102  11 101  10 82  14 83  17
nor-BNI 7 102  13 102  16 77  12* 79  14*
CTOP 7 101  13 99  12 80  16 81  13
Ipoc1NTD 6 111  13 105  14 74  14* 77  16*
Ipoc1nor-BNI 7 107  13 106  13 77  10* 82  16*
Ipoc1CTOP 6 102  16 102  11 81  14 81  19
Repoc1NTD 6 98  14 97  13 64  12w 86  16
Repoc1nor-BNI 6 101  8 100  9 69  11* ,w 86  13
Repoc1CTOP 7 116  10 110  13 67  14* ,w 89  15*
HR (beats per minute)
CON 6 423  24 406  12 413  18 368  21*
NTD 6 415  22 411  23 373  19w 381  14
nor-BNI 7 413  23 406  17 377  21w 379  20
CTOP 7 430  15 412  23 374  20* ,w 378  21*
Ipoc1NTD 6 421  23 411  19 377  13* ,w 379  16*
Ipoc1nor-BNI 7 414  14 414  19 380  21* ,w 375  18*
Ipoc1CTOP 6 415  14 411  14 383  13* ,w 384  15
Repoc1NTD 6 410  29 408  24 371  18* ,w 382  23
Repoc1nor-BNI 6 421  21 422  20 362  5* ,w 381  20
Repoc1CTOP 7 420  22 409  28 367  15* ,w 387  19
RPP (mmHg/min/1000)
CON 6 42  4 42  4 38  4 28  6*
NTD 6 43  6 43  6 31  5w 32  7
nor-BNI 7 42  7 42  7 29  6* ,w 30  6*
CTOP 7 43  6 43  6 30  7* ,w 31  6*
Ipoc1NTD 6 47  5 47  5 28  5* ,w 30  5*
Ipoc1nor-BNI 7 44  7 44  7 29  3* ,w 30  5*
Ipoc1CTOP 6 43  8 43  8 31  6* ,w 31  8*
Repoc1NTD 6 40  9 40  9 24  11* ,w 33  10*
Repoc1nor-BNI 6 43  5 43  5 25  4* ,w 33  6*
Repoc1CTOP 7 48  4 48  4 25  5* ,w 35  6*
Data are presented as mean  SD; data are compared against baseline value across different time points using a repeated measure
analysis of variance (ANOVA) and between groups using one-way ANOVA, with the Bonferroni correction applied for multiple
comparisons if significant F ratios were obtained.
*Po0.05 vs. baseline (within-group comparison).
wPo0.05 vs. control (between-group comparison).
MAP, mean arterial pressure; HR, heart rate; CON, control group; Ipoc, ischemic post-conditioning; Repoc, remifentanil post-
conditioning; NTD, naltrindole; nor-BNI, nor-binaltorphimine; CTOP, D-Phe–Cys–Tyr–D-Trp–Orn–Thr–Pen–Thr–NH2.
Remifentanil post-conditioning
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administered in the in vivo model. Activation of
either d or k opioid receptors is necessary for both
forms of post-conditioning in this model. The m
receptor appears not to be involved in this process.
The efficacy of post-conditioning in the isolated
heart model suggests that this process is at least in
part locally mediated.
Because post-conditioning was first described
with the application of intermittent ischemia, a
number of ligand mediators/triggers have now
been identified, including adenosine,12,17 bradyki-
nin18 and opioids,19 as well as reactive oxygen
species.18 Although chemically diverse, a common
theme underlying these compounds is that they are
all increased during ischemia and reperfusion.20–23
Indeed, some have postulated that ischemic post-
conditioning is another form of staged or con-
trolled reperfusion,24 possibly by altering the levels
of these compounds and maintenance of an acidic
pH.17 Increased expression of endogenous opioids
in heart tissue around the time of myocardial
infarction has long been recognized25 and activa-
tion of opioid receptor subtypes may enhance
ischemic tolerance.26 Activation of d opioid recep-
tors by morphine has been demonstrated to inhibit
the mitochondria permeability transition pore,4 the
putative mechanism for ischemic tolerance and,
therefore, opioid post-conditioning. The signifi-
cance of this study lies is not so much the demon-
stration of post-conditioning by an exogenous
opioid per se, but in the fact that the agent is a
selective m opioid receptor agonist in clinical use
and its potential clinical significance. The unique
pharmacokinetic properties of remifentanil among
the opioids would enable rapid attainment of high
plasma concentrations without the concern of pro-
longed opioid-related side effects. Post-condition-
ing has a small window of effectiveness and rapid
achievement of sufficient plasma concentration
may not be attainable by other opioids with longer
half-lives without resorting to using high doses.
This may result in prolonged sedation and/or
respiratory depression. Another point of signifi-
cance on an experimental level is that remifentanil
is a selective m receptor agonist. With the exception
of one study,5 this receptor subtype has not been
implicated to be involved in post-conditioning.
In contrast to our current results with post-
conditioning, remifentanil mediates its pre-
conditioning cardioprotective effect in part via m
receptors in the intact rat,8 but not in isolated rat
heart preparations.9 Intrathecal morphine at a frac-
tion of the intravenous dose can also pre-condition
the heart,27 an effect attenuated by intrathecal ad-
ministration of the m-specific antagonist CTOP.28
These observations support a role for the activation
of extra-cardiac m receptors in remifentanil pre-con-
ditioning. Such remote pre-conditioning has been
demonstrated with other triggers such as ischemia,
where pre-conditioning of one organ may confer
benefits in a remote organ.29 However, whether
post-conditioning, and in particular opioid post-
conditioning, can be remotely triggered remains to
be defined. Recent work has suggested that post-
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Fig. 3. Comparison of the infarct size (IS) as a percentage of the area
at risk (AAR) for the different treatment groups in vivo. Error
bars5  standard deviations. CON, control group; Ipoc, ischemic
post-conditioning; Repoc, remifentanil post-conditioning; NTD,
naltrindole; nor BNI, nor-binaltorphimine; CTOP, D-Phe–Cys–
Tyr-D-Trp–Orn–Thr–Pen–Thr–NH2. *Po0.05 vs. control.
Fig. 2. Graph showing infarct size (IS) as a percentage of the area
at risk (AAR) for increasing remifentanil dose. The effect of
ischemic post-conditioning (Ipoc) is also shown for comparison.
Results are plotted as mean  standard deviation. *Po0.05.
Q3
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Table 3
Indices of Myocardial Performance of the isolated heart preparations.
n Baseline Ischemia (30min) Rep (10min) Rep (60min) Rep (120min)
LVDP (mmHg)
Con 6 100  13 72  12 91  14 84  21 73  17*
NTD 6 97  8 65  10* 87  7* 71  6* 60  6*
nor-BNI 6 93  9 62  6* 83  9 69  6* 59  7*
CTOP 6 96  11 65  9* 85  15 69  7* 63  4*
Ipoc1NTD 6 98  7 67  7* 80  7* 69  7* 62  6*
Ipoc1nor-BNI 6 100  15 62  11* 87  3 72  11* 60  7*
Ipoc1CTOP 6 112  11 74  14* 83  15* 71  10* 62  9*
Repoc1NTD 6 106  19 72  7* 69  5* ,w 73  9* 57  7*
Repoc1nor-BNI 6 105  18 67  20* 70  4* ,w 75  22* 67  18*
Repoc1CTOP 6 111  23 70  11* 72  9w 66  10 64  5*
LVEDP (mmHg)
Con 6 6  2 9  1 34  5* 21  7* 20  9
NTD 6 6  1 8  2 28  5* 21  5* 16  5*
nor-BNI 6 6  1 9  1* 30  2* 23  5* 16  4*
CTOP 6 7  1 10  2 31  7* 21  5* 17  5*
Ipoc1NTD 6 6  1 8  4 28  6* 20  5* 15  4*
Ipoc1nor-BNI 6 7  2 12  4* 29  7* 21  5* 18  5
Ipoc1CTOP 6 7  1 8  1 28  4* 18  5* 18  7
Repoc1NTD 6 6  1 8  2 29  6* 20  4* 15  5*
Repoc1nor-BNI 6 5  1 10  2* 26  4* 22  7* 15  3*
Repoc1CTOP 6 5  1 8  3 28  2* 22  6* 17  4*
HR (beats per minute)
Con 6 240  37 251  22 265  36 231  50 204  57
NTD 6 259  10 255  33 256  31 232  26 207  30
nor-BNI 6 253  45 245  28 231  31 249  37 216  47
CTOP 6 252  25 267  38 239  33 235  39 199  36
Ipoc1NTD 6 253  24 264  21 233  36 211  31 196  19*
Ipoc1nor-BNI 6 266  28 262  38 241  26 213  30 205  33
Ipoc1CTOP 6 241  24 247  25 226  36 219  42 207  46
Repoc1NTD 6 237  31 249  35 207  48 225  62 194  28
Repoc1nor-BNI 6 246  28 262  25 199  22w 219  16 202  33
Repoc1CTOP 6 261  27 255  22 209  16* 237  30 223  37
dp/dt (mmHg/s)
Con 6 1952  178 1465  156* 1353  165* 1199  75* 1077  69*
NTD 6 1948  393 1572  285* 1343  243* 1272  197* 1153  160*
nor-BNI 6 2092  311 1591  256* 1334  117* 1210  86* 1083  63*
CTOP 6 2009  349 1487  342* 1280  193* 1182  172* 1058  101*
Ipoc1NTD 6 1989  333 1556  329 1351  267* 1227  236* 1153  211*
Ipoc1nor-BNI 6 2035  216 1676  305* 1439  174* 1246  131* 1150  109*
Ipoc1CTOP 6 2001  275 1549  366 1292  289* 1145  205* 1052  155*
Repoc1NTD 6 2117  235 1673  220* 1243  95* 1181  90* 1114  77*
Repoc1nor-BNI 6 1931  385 1522  330* 1246  156* 1164  165* 1111  131*
Repoc1CTOP 6 2014  373 1550  274* 1226  105* 1156  90* 1102  90*
 dp/dt (mmHg/s)
Con 6 1601  342 1363  217 1178  123 1061  70 960  83
NTD 6 1447  193 1272  172* 1168  112* 1062  103* 989  71*
nor-BNI 6 1559  204 1316  140* 1241  173* 1122  124* 997  61*
CTOP 6 1541  348 1345  240 1245  185 1105  149* 1008  98*
Ipoc1NTD 6 1516  174 1217  93 1164  32 1068  85* 990  33*
Ipoc1nor-BNI 6 1548  175 1222  116 1082  59* 987  48* 954  27
Ipoc1CTOP 6 1560  292 1228  130 1123  132 1058  112* 969  97*
Repoc1NTD 6 1676  334 1302  174* 1175  164* 1062  160* 975  140*
Repoc1nor-BNI 6 1533  212 1208  63* 1107  68* 1047  98* 981  91*
Repoc1CTOP 6 1617  235 1344  273 1148  112 1064  86* 1012  52*
Data are presented as mean  SD; data are compared against baseline value across different time points using a repeated measure
analysis of variance (ANOVA) and between groups using one-way ANOVA, with the Bonferroni correction applied for multiple
comparisons if significant F ratios were obtained. Baseline values obtained just before induction of ischemia.
*Po0.05 vs. baseline (within-group comparison).
wPo0.05 vs. control (between-group comparison).
LVDP, left ventricular developed pressure (mmHg); LVEDP, left ventricular end diastolic pressure; HR, heart rate; dP/dt, positive left
ventricular pressure derivative (mmHg/s); dP/dt, negative left ventricular pressure derivative (mmHg/s); CON, control group; Ipoc,
ischemic postconditioning; Repoc, remifentanil post-conditioning; NTD, naltrindole; nor-BNI, nor-binaltorphimine; CTOP, D-Phe–Cys–
Tyr-D-Trp–Orn–Thr–Pen–Thr–NH2.
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conditioning may be remotely triggered by indu-
cing ischemia in a distant organ.30 It is not possible
to infer from our results whether remifentanil post-
conditioning is an entirely locally and/or remotely
triggered as the results are similar both in the intact
animal and in the isolated rat.
Most previous observations regarding the rela-
tive roles of opioid receptors in post-conditioning
have implicated the d and k receptors,4,5,31 as our
current data also suggest. Our observations, how-
ever, are inconsistent with those from Zatta et al.,5
where the investigators demonstrated that the
effects of ischemic post-conditioning may be in-
hibited by the m opioid receptor antagonist CTAP
at a dose between 0.09 and 0.19 umol/kg. The dose
of 1 mg/kg (0.94mmol/kg) of CTOP used in this
study is higher on a molar basis than the dose of
CTAP used by Zatta and colleagues and thus the
difference cannot be account for by an insufficient
dose. Further inconsistencies are also seen with the
d receptor in post-conditioning. A study evaluating
morphine post-conditioning in the isolated heart
model demonstrated that its protective effect was
not attenuated by the d receptor antagonist NTD.32
This finding contrasts with previous work where a
specific d agonist was effective in producing post-
conditioning benefits.19 Therefore, the relative roles
of opioid receptors in post-conditioning will re-
quire further definition, as it will influence the
choice of the exogenous opioid used.
Cardiac post-conditioning has led to exciting
prospects for clinical cardiac protection as it re-
moves the Achilles’ heel of pre-conditioning, that
of timing the intervention before the index is-
chemic event. Pharmacological post-conditioning
can potentially further circumvent the limitations
posed by ischemic post-conditioning in the clinical
setting. The iatrogenic induction of myocardial
ischemia could harm the diseased coronaries or
may be arrhythmogenic. Pharmacological post-
conditioning may be more versatile as it can easily
be applied in the post-cardiopulmonary bypass
setting, in patients undergoing thrombolysis as
well as coronary angioplasty. Should opioid post-
conditioning be shown to be clinically beneficial,
remifentanil would indeed be a logical choice for
this purpose.
In conclusion, data from this study have confir-
med the efficacy of remifentanil post-conditioning
as being equal to that of ischemic post-conditioning
and both involve the activation of k and d recep-
tors. It would be interesting to determine the
subcellular mechanisms involved in remifentanil
post-conditioning to see whether they are common
to those elicited by other opioids, ligands or ische-
mia. Should obvious differences be apparent, con-
sideration may be made to a multimodal approach
to post-conditioning, much analogous to the well-
proven practice of multimodal analgesia.
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